Piedmont Heart Institute cardiologists Christopher Meduri, M.D., Vivek Rajagopal, M.D., and Mani Vannan, M.D., recently completed the first two implantations of the TriCinch Coil System in the U.S. at Piedmont Atlanta Hospital, marking the initiation of a U.S. Early Feasibility Study from 4TECH Inc.
“We are pleased to be the first center in the U.S. to implant the TriCinch Coil System,” said Dr. Meduri, co-medical director of Piedmont’s Marcus Heart Valve Center. “Both procedures went smoothly, and the device was easy to implant.”
Tricuspid regurgitation is a common condition that is age-related and difficult-to-manage, in which blood “backflows” into the right atrium of the heart. Severe tricuspid regurgitation affects more than 1.6 million people in the United States and treatment options are limited.
The 4TECH TriCinch Coil System is a percutaneous direct annuloplasty device designed to reduce tricuspid regurgitation through tricuspid valve remodeling via a unique nitinol coil anchor that is tensioned by a nitinol stent in the inferior vena cava.
“Having a technology like the TriCinch Coil System in our structural heart toolkit allows us to treat a wide range of patients suffering from tricuspid regurgitation, who are at high risk for open heart surgery, in a safe and simple manner,” said Dr. Meduri.
The 4TECH TriCinch™ Coil System for Transcatheter Tricuspid Valve Repair is in the early clinical phase of development and is not available for sale in any region of the world.
